Valsartan is an orally active antihypertensive agent which belongs to the category of angiotensin II type I receptor antagonists. Valsartan is used for the treatment of heart failure, hypertension, myocardial infraction and diabetic nephropathy. A new stability indicating RP-HPLC was proposed for the quantification of Valsartan by using an ion-pairing agent, tetra butyl ammonium hydrogen sulphate. Mobile phase mixture consisting of 10 mM tetra butyl ammonium hydrogen sulphate and methanol (25: 75, v/v) was selected with a flow rate of 1 ml/min using Agilent C18 column (Detection wavelength 250 nm). The LOD and LOQ were found to be 0.0291 μg/mL and 0.0897 μg/mL respectively. Linearity was observed over the concentration 0.1-50 μg/mL with linear regression equation, y = 36571x + 13532 and the method is precise, accurate and robust. Stress degradation studies were performed and the method was found to be selective and specific.